Mild Cognitive Impairment Clinical Trial
— engAGEOfficial title:
engAGE: Managing cognitivE decliNe throuGh Theatre Therapy, Artificial Intelligence and Social Robots drivEn Interventions
The objectives of the engAGE project are to counteract and slow down cognitive decline progression, to enhance the intrinsic capacity of the users, and to support the wellbeing of older persons with mild cognitive impairment (MCI) by providing an ecosystem of services based on an innovative system that integrates social robots.
Status | Recruiting |
Enrollment | 78 |
Est. completion date | June 24, 2024 |
Est. primary completion date | June 24, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 65 Years and older |
Eligibility | Inclusion Criteria: - mild cognitive impairment (MCI); - Montreal Cognitive Assessment (MoCA) score 21 - 25; - Memory Assessment Clinics - Questionnaire (MAC-Q) = 25; - Reisberg scale 2 - 4; - Clinical Frailty Scale score 1 - 3; - 4-items GDS score = 1; - have an informal caregiver to support in carrying out the main daily activities. Exclusion Criteria: - lack of informal caregivers; - significant visual or hearing impairment. |
Country | Name | City | State |
---|---|---|---|
Italy | IRCCS INRCA Hospital | Ancona | |
Norway | Karde A/S | Oslo | |
Switzerland | HUG | Geneva |
Lead Sponsor | Collaborator |
---|---|
Istituto Nazionale di Ricovero e Cura per Anziani | European Union |
Italy, Norway, Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in perceived stability of cognitive status by the older adults | The Memory Assessment Clinics - Questionnaire (MAC-Q) is a 6-item scale that uses a 5-item Likert scale from "much better now"=1 to "much worse now"=5, and the last question scores double. The questionnaire asks the person to compare his or her memory with a previous period to measure age-related memory decline. Five items address specific situations frequently reported as problematic by those who experience memory loss with age. One item is a global item assessing general memory decline. A cutoff of 25 points or more indicates that the individual has a memory disorder. | baseline and 6 months later | |
Secondary | Change in cognitive impairment in older adults | The Montreal Cognitive Assessment (MoCA) is a screening assessment for detecting cognitive impairment. The MoCA assesses several cognitive domains: the short-term memory recall task (5 points), visuospatial abilities (4 points), alternation task (1 point), verbal abstraction task (1 point), attention, concentration, and working memory (6 points), language (6 points), abstract reasoning (2 points), and orientation to time and place (6 points).Scores on the MoCA range from zero to 30. A score of 26 and higher is considered normal. | baseline and 6 months later | |
Secondary | Change in depression in older adults | The 4-items Geriatric Depression Scale (GDS) is a 4-items scale whose answers are yes or no. If all the items are answered negatively then the depression is excluded; if only one item is answered positively then the situation is uncertain; if at least 2 items are answered positively, the patient is depressed. | baseline and 6 months later | |
Secondary | Change in frailty status in older adults | The Clinical Frailty Scale (CFS) is a descriptive scale divides the older participants into 9 classes based on the information provided by them and their relatives: between 1 and 3 the patient is non-frail, pre-frail if 4, he is frail from 5 to 9. | baseline and 6 months later | |
Secondary | Change in mental well being in older adults | The Warwick-Edinburgh Mental Wellbeing Scales (WEMWBS). is used to enable the measuring of mental wellbeing in the general population. The 12-item scale WEMWBS has 5 response categories, summed to provide a single score. Scores range from 7 to 35 and higher scores indicate higher positive mental wellbeing. | baseline and 6 months later | |
Secondary | Change in quality of life in older adults | The EuroQoL-5D-5L scale consists of five dimensions: mobility, independence, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, mild problems, moderate problems, severe problems and extreme problems. The numbers from the five dimensions can be combined into a 5-digit number that describes the health status of the participant. | baseline and 6 months later | |
Secondary | Change in acceptability of the engAGE system in older adults | Acceptability will be assessed by the Unified Theory of Acceptance and Use of Technology test (UTAUT). It's a standardized instrument for measuring the likelihood of success for new technology introductions and helps to understand the drivers of its acceptance.
The questionnaire has 52 questions distributed in 4 key constructs: 1) performance expectancy, 2) effort expectancy, 3) social influence, and 4) facilitating conditions. Each question are based on a Likert-type 5-point scale ranging from 1 = strongly disagree to 5 = strongly agree. Increments are integers between 1 to 5. |
baseline and 6 months later | |
Secondary | Change in quality of life in informal caregivers | The EuroQoL-5D-5L scale consists of five dimensions: mobility, independence, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, mild problems, moderate problems, severe problems and extreme problems. The numbers from the five dimensions can be combined into a 5-digit number that describes the health status of the participant. | baseline and 6 months later | |
Secondary | Change in mental well being in informal caregivers | The Warwick-Edinburgh Mental Wellbeing Scales (WEMWBS) is used to enable the measuring of mental wellbeing in the general population. The 12-item scale WEMWBS has 5 response categories, summed to provide a single score. Scores range from 7 to 35 and higher scores indicate higher positive mental wellbeing. | baseline and 6 months later | |
Secondary | Change in caregiver burden | The Zarit Burden Interview (ZBI) is a caregiver self-report measure, containing 22 items. Each item on the interview is a statement which the caregiver is asked to endorse using a 5-point scale. Response options range from 0 (Never) to 4 (Nearly Always). | baseline and 6 months later |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04513106 -
Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial
|
N/A | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Active, not recruiting |
NCT03167840 -
Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment
|
N/A | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Not yet recruiting |
NCT05041790 -
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment
|
Phase 4 | |
Recruiting |
NCT04121156 -
High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT03605381 -
MORbidity PRevalence Estimate In StrokE
|
||
Completed |
NCT02774083 -
Cognitive Training Using Feuerstein Instrumental Enrichment
|
N/A | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Enrolling by invitation |
NCT06023446 -
Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
|
||
Completed |
NCT04567745 -
Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers
|
Phase 1 | |
Recruiting |
NCT05579236 -
Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
|
||
Completed |
NCT03583879 -
Using Gait Robotics to Improve Symptoms of Parkinson's Disease
|
N/A | |
Terminated |
NCT02503501 -
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
|
Phase 2 | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Active, not recruiting |
NCT05204940 -
Longitudinal Observational Biomarker Study
|
||
Recruiting |
NCT02663531 -
Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease
|
N/A | |
Recruiting |
NCT06150352 -
Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
|
||
Recruiting |
NCT03507192 -
Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.
|
N/A |